News
RLFTY
0.423
NaN%
--
MindMaze Therapeutics publishes presentation for June 25, 2026 AGM
PUBT · 3d ago
MindMaze Therapeutics shareholders reject conditional capital increase at AGM
PUBT · 4d ago
MindMaze Therapeutics Publishes Invitation to 2026 Annual General Meeting
PUBT · 06/03 04:45
MindMaze Therapeutics secures CHF 8 million strategic equity investment from Neuro.io Group
PUBT · 05/26 04:50
MindMaze Therapeutics signs channel partnership with Vibra Healthcare for US expansion
PUBT · 05/12 05:09
MindMaze Therapeutics partners with Vibra Healthcare to expand U.S. neurotherapeutics footprint
PUBT · 04/30 05:03
MindMaze Therapeutics FY25 net loss totals CHF 9.9 million; revenue CHF 0.6 million
PUBT · 04/15 05:06
MindMaze RWE study shows high-dose neurorehab boosts stroke recovery vs standard care
Reuters · 03/31 05:04
Baader Bank initiates coverage on MindMaze Therapeutics with buy rating and CHF 1.8 target price
Reuters · 03/19 05:32
MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
Barchart · 03/18 21:35
MindMaze Therapeutics names Zach Henderson CEO and appoints Alexandre Capet Chief Operating and Strategy Officer
Reuters · 03/12 05:47
MindMaze Therapeutics Holding SA Publishes March 2026 Investor Presentation
Reuters · 03/03 07:11
MindMaze Therapeutics board members Van Beek and Stünkel step down
Reuters · 03/03 06:51
Edison Initiates Coverage on MindMaze Therapeutics Holding SA
Reuters · 12/18/2025 14:12
Relief Therapeutics and NeuroX Complete Merger to Form MindMaze Therapeutics
Reuters · 12/15/2025 06:02
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
Barchart · 12/14/2025 19:20
Relief Therapeutics and NeuroX Reveal Joint Presentation and Financial Outlook Ahead of Anticipated Merger
Reuters · 11/25/2025 06:02
Relief Therapeutics Shareholders Approve Merger with NeuroX
Reuters · 11/14/2025 17:22
Relief Therapeutics Reports Positive Bioequivalence Results for RLF-OD032 in PKU Study
Reuters · 10/29/2025 06:00
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
Barchart · 10/28/2025 21:20
More
Webull provides a variety of real-time RLFTY stock news. You can receive the latest news about MindMaze Therapeutics Holding SA through multiple platforms. This information may help you make smarter investment decisions.
About RLFTY
MindMaze Therapeutics Holding SA, formerly known as RELIEF THERAPEUTICS Holding SA, is a Switzerland-based company that engages in research, development, production, and sale of biotechnology, pharmaceutical, diagnostic, therapeutic, chemical, and cosmetic products. The Company acquires and manages patents, licenses, and intellectual property, provides preclinical, clinical, and regulatory services, and may establish subsidiaries worldwide. The Company also participates in the acquisition, holding, and financing of interests in companies, offers management services to affiliates, and develops scientific and economic solutions for disease treatment and therapeutic approaches. Additionally, the Company may acquire, hold, and sell trademarks and other IP rights globally, and provide or obtain financing through loans or guarantees to support its corporate purpose.